QIAGEN & INOVIO Expand Collaboration to Develop Next Generation Sequencing (NGS) Companion Diagnostic for INOVIO’s VGX-3100...
February 24 2021 - 1:45AM
Business Wire
- Liquid biopsy-based precision test guides patient selection and
offers potential for cost-effective, non-invasive alternative to
surgical removal of cervical lesions
- QIAGEN’s bioinformatic expertise raises predictive biomarker
power in INOVIO’s patient selection
- First-in-class next generation sequencing (NGS) assay designed
for use on Illumina NextSeq™ 550Dx
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and INOVIO
Pharmaceuticals (NASDAQ: INO) today announced an extension of their
partnership with a new master collaboration agreement to develop
liquid biopsy-based companion* diagnostic products based on
next-generation sequencing (NGS) technology to complement INOVIO’s
therapies. (*Complementary when referring to the US regulatory
pathway.)
The initial project in this expanded collaboration focuses on
the co-development of a diagnostic test that identifies women who
are most likely to benefit from clinical use of VGX-3100, INOVIO's
immunotherapy to treat advanced cervical dysplasia associated with
the human papillomavirus (HPV). QIAGEN’s bioinformatic expertise
will further increase the predictive power of INOVIO’s preliminary
biomarker signature – and the assay will now be developed for use
on the Illumina NextSeq™ 550Dx platform, the first development
based on a partnership QIAGEN and Illumina signed in October
2019.
VGX-3100 is INOVIO’s late-stage DNA immunotherapy candidate. It
is currently in two Phase 3 trials (REVEAL 1 and REVEAL 2), with
the potential to become the first non-surgical treatment for
advanced pre-cancerous cervical lesions associated with the virus
(HPV-16 and HPV-18).
"As we advance our DNA medicines platform, we are always looking
for ways to drive innovation with our own technology or that of a
creative and accomplished partner. QIAGEN is contributing an
extensive track record of developing and commercializing novel
diagnostic tests,” said Dr. J. Joseph Kim, INOVIO’s President and
CEO. “INOVIO is developing VGX-3100 as a non-surgical treatment for
cervical pre-cancer and pre-treatment biomarkers we have discovered
could be a targeted way to identify patients most likely to respond
to treatment. The goal is to increase the absolute efficacy of the
immunotherapy."
Please find the full press release here.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20210223006239/en/
QIAGEN
Investor Relations John Gilardi +49 2103 29 11711 Phoebe
Loh +49 2103 29 11457 e-mail: ir@QIAGEN.com
Public Relations Thomas Theuringer +49 2103 29 11826
Robert Reitze +49 2103 29 11676 e-mail: pr@QIAGEN.com
INOVIO Investors Ben Matone 484-362-0076
ben.matone@inovio.com
Media Jeffrey C. Richardson 267-440-4211
jeff.richardson@inovio.com
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From May 2024 to Jun 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Jun 2023 to Jun 2024